Search Results - "СЕРДЕЧНО-СОСУДИСТЫЕ ФАКТОРЫ РИСКА"

1

Academic Journal

Clinical and epidemiological aspects of chronic myeloproliferative diseases in the RS (Ya)

Authors: I.E. Solovieva, L.D. Terekhova, T.N. Aleksandrova, I.I. Mulina, N.I. Pavlova, V.N. Yadrikhinskaya

Source: Yakut Medical Journal. :37-40

Subject Terms: 2. Zero hunger, cardiovascular risk, сердечно-сосудистые факторы риска, тромбозы, хронические миелопролиферативные заболевания, chronic myeloproliferative diseases, thrombosis, 3. Good health

2

Academic Journal

Incidence of cardiovascular risk factors in patients with concomitant atherosclerotic impairment of coronary and carotid arteries ; Incidența factorilor de risc cardiovascular la pacienții cu afectare aterosclerotică concomitentă a arterelor coronare și carotid ; Частота факторов риска сердечно-сосудистых заболеваний у пациентов с сопутствующим атеросклеротическим поражением коронарных и сонных артерий.

Authors: Vataman, Eleonora, Anestiadi, Vasile, Calenici, Eugeniu, Grossu, Ala

Source: Bulletin of the Academy of Sciences of Moldova. Medical Sciences; Vol. 61 No. 1 (2019): Medical Sciences; 161-165 ; Buletinul Academiei de Științe a Moldovei. Științe medicale; Vol. 61 Nr. 1 (2019): Ştiinţe medicale; 161-165 ; Вестник Академии Наук Молдовы. Медицина; Том 61 № 1 (2019): Медицина; 161-165 ; 1857-0011

Subject Terms: сердечно-сосудистые факторы риска, атеросклеротические поражения, коронарные и сонные артерии., cardiovascular risk factors, atherosclerotic impairment, coronary and carotid arteries, factori de risc cardiovascular, afectare aterosclerotică, artere coronare și carotide

File Description: application/pdf

Relation: https://bulmed.md/bulmed/article/view/3007/3007; https://bulmed.md/bulmed/article/view/3007

Availability: https://bulmed.md/bulmed/article/view/3007

View record from BASE

3

Academic Journal

Incidența factorilor de risc cardiovascular la pacienții cu afectare aterosclerotică concomitentă a arterelor coronare și carotid

Authors: Vataman, E.B., Anestiadi, V.V., Calenici, E., Grossu, A.G.

Source: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 61 (1) 161-165

Subject Terms: factori de risc cardiovascular, afectare aterosclerotică, artere coronare și carotide, cardiovascular risk factors, atherosclerotic impairment, coronary and carotid arteries, сердечно-сосудистые факторы риска, атеросклеротические поражения, коронарные и сонные артерии.

File Description: application/pdf

Relation: https://ibn.idsi.md/vizualizare_articol/75822; urn:issn:18570011

Availability: https://ibn.idsi.md/vizualizare_articol/75822

View record from BASE

4

Academic Journal

Cardiovascular risk factors in childhood obesity

Authors: Romanciuc, L.V., Романчук, Л.В.

Source: Buletin de Perinatologie 84 (3) 19-23

Subject Terms: obezitate, factori de risc cardiovascular, copii, ожирение, сердечно-сосудистые факторы риска, дети

File Description: application/pdf

Relation: https://ibn.idsi.md/vizualizare_articol/90355; urn:issn:18105289

Availability: https://ibn.idsi.md/vizualizare_articol/90355

View record from BASE

5

Academic Journal

MENOPAUSE AND CARDIOVASCULAR RISK

Authors: D. A. Anichkov, N. A. Shostak, A. D. Zhuravleva

Source: Рациональная фармакотерапия в кардиологии, Vol 1, Iss 1, Pp 37-42 (2015)

Subject Terms: менопауза, сердечно-сосудистые факторы риска, модификация образа жизни, фармакологическое лечение, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/341; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

Access URL: https://doaj.org/article/464d263be84041c8b1f19f99cbf0c699

View record in DOAJ Full Text Finder

6

Academic Journal

CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: MECHANISMS FOR THE ACCELERATED DEVELOPMENT OF ATHEROSCLEROSIS, DIAGNOSIS, CORRECTION CAPABILITIES ; Сердечно-сосудистые осложнения при системной красной волчанке: механизмы ускоренного развития атеросклероза, диагностика, возможности коррекции

Authors: A. V. Arshinov, N. Yu. Levshin, I. G. Maslova, А. В. Аршинов, Н. Ю. Левшин, И. Г. Маслова

Source: Rheumatology Science and Practice; Vol 55, No 3 (2017); 304-310 ; Научно-практическая ревматология; Vol 55, No 3 (2017); 304-310 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20173

Subject Terms: лечение сердечно-сосудистых событий, atherosclerosis, nontraditional cardiovascular risk factors, treatment of cardiovascular events, атеросклероз, нетрадиционные сердечно-сосудистые факторы риска

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2383/1583; Насонов ЕЛ. Антифосфолипидный синдром. Москва: Литтерра; 2004. 440 с. [Nasonov EL. Antifosfolipidnyi sindrom [Antiphospholipid syndrome]. Moscow: Litterra; 2004. 440 p.].; EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67:195-205. doi:10.1136/ard.2007.070367; Liu Z, Davidson A. Taming lupus – a new understanding of pathogenesis is leading to clinical advances. Nature Medicine. 2012;18(6):871-82. doi:10.1038/nm.2752; D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007;369(9561):587-96. doi:10.1016/S0140- 6736(07)60279-7; Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med. 1985;55(216):87-98.; Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60(2):221-5. doi:10.1016/0002-9343(76)90431-9; Bjö rnadal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964- 95. J Rheumatol. 2004;31(4):713-9.; Nossent J, Cikes N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus. 2007;16(5):309-17. doi:10.1177/0961203307077987; Amaya-Amaya J, Sarmiento-Monroy JC, Caro-Moreno J, et al. Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. Autoimmune Dis. 2013;2013:Article ID 794383, 20 p. doi:10.1155/2013/794383; McMahon M, Skaggs B. Pathogenesis and treatment of atherosclerosis in lupus. Rheum Dis Clin North Am. 2014;40(3):475-95.; Van Leuven SI, van Wijk DF, Volger OL, et al. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis. 2010;211(1):231-6. doi:10.1016/j.atherosclerosis.2010.01.043; Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res. 2004;114(5-6):593-5. doi:10.1016/j.thromres.2004.07.012; Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 2012;176(8):708-19. doi:10.1093/aje/kws130; Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2331-7. doi:10.1002/1529- 0131(200110)44:103.0.CO;2-I; Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001;13:345-51. doi:10.1097/00002281-200109000-00002; Bruce IN. 'Not only. but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford). 2005;44(12):1492-502. doi:10.1093/rheumatology/kei142; Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates ofmyocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Amer J Epidemiol. 1997;145(5):408-15. doi:10.1093/oxfordjournals.aje.a009122; Kiani AN, Magder LS, Petri M. Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. Rheumatol Int. 2012;32(9):2701-5. doi:10.1007/s00296-011-2048-y; Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Amer J Med. 2006;119(8):700-6. doi:10.1016/j.amjmed.2005.11.034; Ильина АЕ, Клюквина НГ, Александрова ЕН и др. Атеросклеротическое поражение сосудов при системной красной волчанке и антифосфолипидном синдроме у мужчин. Клиническая медицина. 2006;(4):23-8 [Il'ina AE, Klyukvina NG, Aleksandrova EN, et al. Atherosclerotic vascular lesions in systemic lupus erythematosus and antiphospholipid syndrome in men. Klinicheskaya Meditsina. 2006;(4):23-8 (In Russ.)].; McMahon M, Grossman J, Chen W, et al. Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus. Lupus. 2006;15:59-69. doi:10.1177/0961203306071668; Sinicato NA, da Silva Cardoso PA, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev. 2013;19(1):15-9.; Narshi CB, Giles IP, Rahman A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus. 2011;20(1):5-13. doi:10.1177/0961203310382429; Ames PR, Margarita A, Sokoll KB, et al. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis. 2005;64(2):315-7. doi:10.1136/ard.2004.023952; Ames PR, Margarita A, Alves JD. Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rev Allergy Immunol. 2009;37(1):29-35. doi:10.1007/s12016-008-8099-5; Gresele P, Migliacci R, Vedovati MC, et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res. 2009;123(3):444-51. doi:10.1016/j.thromres.2008.05.015; Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus. 2010;19(4):419-23. doi:10.1177/0961203309360541; O'Neill SG, Giles I, Lambrianides A, et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2010;62(3):845-54. doi:10.1002/art.27286; Mandal K, Foteinos G, Jahangiri M, et al. Role of antiheat shock protein 60 autoantibodies in atherosclerosis. Lupus. 2005;14(9):742-6. doi:10.1191/0961203305lu2212oa; Fangtham M, Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep. 2013;15(9):360. doi:10.1007/s11926-013-0360-0; Motoki Y, Nojima J, Yanagihara M, et al. Anti-phospholipid antibodies contribute to arteriosclerosis in patients with systemic lupus erythematosus through induction of tissue factor expression and cytokine production from peripheral blood mononuclear cells. Thromb Res. 2012;130(4):667-73. doi:10.1016/j.thromres.2011.11.048; Loeffen R, Spronk HM, ten Cate H. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost. 2012;10(7):1207-16. doi:10.1111/j.1538- 7836.2012.04782.x; Boles J, Mackman N. Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus. 2010;19(4):370-8. doi:10.1177/0961203309360810; Mayadas TN, Tsokos GC, Tsuboi N. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation. 2009;120:2012-24. doi:10.1161/CIRCULATIONAHA.108.771170; Tsokos GC. Mechanisms of disease systemic lupus erythematosus. N Engl J Med. 2011;365:2110-21. doi:10.1056/NEJMra1100359; Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004;103:3677-83. doi:10.1182/blood-2003-09-3198; Ruiz-Limon P, Barbarroja N, Perez-Sanchez C, et al. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. Ann Rheum Dis. 2015;74(7):1450-8. doi:10.1136/annrheumdis-2013-204351; Thacker SG, Duquaine D, Park J, et al. Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus. 2010;19(3):288-99. doi:10.1177/0961203309353773; Thacker SG, Zhao W, Smith CK, et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum. 2012;64(9):2975-85. doi:10.1002/art.34504; Trinchieri G. Type I interferon: friend or foe? J Exp Med. 2010;207(10):2053-63. doi:10.1084/jem.20101664; Knight JS, Kaplan MJ. Cardiovascular disease in lupus: insights and updates. Curr Opin Rheumatol. 2013;25(5):597-605. doi:10.1097/BOR.0b013e328363eba3; Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532-5. doi:10.1126/science.1092385; Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol. 2012;198(5):773-83. doi:10.1083/jcb.201203170; Hakkim A, Furnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 2010;107(21):9813-8. doi:10.1073/pnas.0909927107; Leffler J, Martin M, Gullstrand B, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol. 2012;188(7):3522-31. doi:10.4049/jimmunol.1102404; Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra20. doi:10.1126/scitranslmed.3001201; Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra19.; Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol. 2011;187(1):538-52. doi:10.4049/jimmunol.1100450; Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482-94. doi:10.1056/NEJMra071014; Vieira-de-Abreu A, Campbell RA, Weyrich AS, et al. Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immunopathol. 2012;34(1):5-30. doi:10.1007/s00281-011-0286-4; Tam LS, Fan B, Li EK, et al. Patients with systemic lupus erythematosus show increased platelet activation and endothelial dysfunction induced by acute hyperhomocysteinemia. J Rheumatol. 2003;30(7):1479-84.; Duffau P, Seneschal J, Nicco C, et al. Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med. 2010;2(47):47ra63. doi:10.1126/scitranslmed.3001001; Kaiser R, Li Y, Chang M, et al. Genetic risk factors for thrombosis in systemic lupus erythematosus. J Rheumatol. 2012;39(8):1603- 10. doi:10.3899/jrheum.111451; Chang YH, Lin IL, Tsay GJ, et al. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Biochem. 2008;41(12):955-9. doi:10.1016/j.clinbiochem.2008.04.012; Bahrehmand F, Vaisi-Raygani A, Kiani A, et al. Matrix metalloproteinase-2 functional promoter polymorphism G1575A is associated with elevated circulatory MMP-2 levels and increased risk of cardiovascular disease in systemic lupus erythematosus patients. Lupus. 2012;21(6):616-24. doi:10.1177/0961203312436857; McMahon M, Grossman J, Skaggs B, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 2009;60(8):2428-37. doi:10.1002/art.24677; Zampieri S, Iaccarino L, Ghirardello A, et al. Systemic lupus erythematosus, atherosclerosis, and autoantibodies. Ann N Y Acad Sci. 2005;1051:351-61. doi:10.1196/annals.1361.077; Kawai VK, Solus JF, Oeser A, et al. Novel cardiovascular risk prediction models in patients with systemic lupus erythematosus. Lupus. 2011;20(14):1526-34. doi:10.1177/0961203311420317; Symmons DPM, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 2011;7(7):399-408. doi:10.1038/nrrheum.2011.75; Urowitz MB, Gladman D, Ibanez D, et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62:881-7. doi:10.1002/acr.20122; Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthr Rheum. 2013;43(1):77-95. doi:10.1016/j.semarthrit.2012.12.002; Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol. 2009;25(10):567-79. doi:10.1016/S0828-282X(09)70715-9; Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55(12):1266-73. doi:10.1016/j.jacc.2010.01.020; Pons-Estel GJ, Gonzalez LA, Zhang J, et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford). 2009;487:817-22. doi:10.1093/rheumatology/kep102; Gustafsson J, Simard JF, Gunnarsson I, et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther. 2012;14(2):46. doi:10.1186/ar3759; Nikpour M, Harvey PJ, Ibanez D, et al. High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. Arthritis Rheum. 2012;64(9):3052-3. doi:10.1002/art.34541; Wu GC, Liu HR, Leng RX, et al. Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis. Autoimmun Rev. 2016;15(1):22-37. doi:10.1016/j.autrev.2015.10.002; Tselios K, Sheane BJ, Gladman DD, Urowitz MB. Optimal monitoring for coronary heart disease risk in patients with systemic lupus erythematosus: A systematic review. J Rheumatol. 2016;43(1):54-65. doi:10.3899/jrheum.150460; Petri M, Magder L. SLE cardiovascular risk equation. Lupus. 2013;22(1):3-5.; Jastrzebska M, Czok ME, Guzik P. Autoimmune diseases, their pharmacological treatment and the cardiovascular system. Cardiol J. 2013;20(6):569-76. doi:10.5603/CJ.2013.0156; Fardet L. Corticosteroid-induced clinical adverse events: Frequency, risk factors and patient's opinion. Br J Dermatol. 2007;157:142-8. doi:10.1111/j.1365-2133.2007.07950.x; Nakajima A, Doki K, Homma M, et al. Investigation of glucocorticoidinduced side effects in patients with autoimmune diseases. Yakugaku Zasshi. 2009;129:445-50. doi:10.1248/yakushi.129.445; Linos E, Fiorentino D, Lingala B. Atherosclerotic cardiovascular disease and ermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis Res Ther. 2013;15:1-5. doi:10.1186/ar4135; Tisseverasinghe A, Bernatsky S, Pineau C. Arterial events in persons with dermatomyositis and polymyositis. J Rheumatol. 2009;36:1-4. doi:10.3899/jrheum.090061; Selzer F, Sutton-Tyrrell K, Fitzgerald S, et al. Vascular stiffness in women with systemic lupus erythematosus. Hypertension. 2001;37(4):1075-82. doi:10.1161/01.HYP.37.4.1075; Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2399-406. doi:10.1056/NEJMoa035471; Rahman P, Gladman DD, Urowitz MB, et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol. 1999;26(2):325-30.; Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010;62(3):863-8. doi:10.1002/art.27289; Law G, Magder LS, Fang H, et al. Hydroxychloroquine Reduces Thrombosis (BOTH ARTERIAL AND VENOUS) in Systemic LUPUS Erythematosus, Particularly in Antiphospholipid Positive Patients. American College of Rheumatology 76th Annual Meeting; November 9-14, 2012. Washington, D.C.; 2012.; Costedoat-Chalumeau N, Hulot JS. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology. 2007;46:808-10. doi:10.1093/rheumatology/kel402; Iudici M, Fasano S, Gabriele Falcone L, et al. Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. Rheumatology (Oxford). 2016;55(9):1623-30. doi:10.1093/rheumatology/kew231; Van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ, et al. Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(–/–) mice. Ann Rheum Dis. 2012;71(3):408-14. doi:10.1136/annrheumdis-2011-200071; Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2015;36(8):482-9. doi:10.1093/eurheartj/ehu403; Aprahamian T, Bonegio RG, Richez C, et al. The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol. 2009;182(1):340-6. doi:10.4049/jimmunol.182.1.340; Zhao W, Thacker SG, Hodgin JB, et al. The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. J Immunol. 2009;183(4):2729-40. doi:10.4049/jimmunol.0804341; Zuarez-Rojas JG, Medina-Urrutia AX, Jorge-Galarza E, et al. Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial. Lupus. 2012;21(1):27-35. doi:10.1177/0961203311422096; Khattri S, Zandman-Goddard G. Statins and autoimmunity. Immunol Res. 2013;56(2-3):348-57. doi:10.1007/s12026-013- 8409-8; Willis R, Seif AM, McGwin G Jr, et al. Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multiethnic US cohort. Clin Exp Rheumatol. 2014;32(2):162-7.; Lawman S, Mauri C, Jury EC, et al. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol. 2004;173(12):7641-6. doi:10.4049/jimmunol.173.12.7641; Aprahamian T, Bonegio R, Rizzo J, et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol. 2006;177(5):3028- 34. doi:10.4049/jimmunol.177.5.3028; Petri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis. 2011;70:760-5. doi:10.1136/ard.2010.136762; Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64(1):285-96. doi:10.1002/art.30645

Availability: https://rsp.mediar-press.net/rsp/article/view/2383
https://doi.org/10.14412/1995-4484-2017-304-310

View record from BASE

7

Academic Journal

MENOPAUSE AND CARDIOVASCULAR RISK

Authors: A. D. Zhuravleva, Shostak Na, D. A. Anichkov

Source: Рациональная фармакотерапия в кардиологии, Vol 1, Iss 1, Pp 37-42 (2015)

Subject Terms: cardiovascular risk factors, сердечно-сосудистые факторы риска, фармакологическое лечение, menopause, модификация образа жизни, RM1-950, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, pharmacological treatment, RC666-701, lifestyle modification, менопауза, Diseases of the circulatory (Cardiovascular) system, Therapeutics. Pharmacology

Access URL: https://www.rpcardio.com/jour/article/download/341/360
https://doaj.org/article/464d263be84041c8b1f19f99cbf0c699
https://doaj.org/article/3474c4371d1b48478d89ccc803c5644f
https://www.rpcardio.com/jour/article/download/341/360
https://doaj.org/article/464d263be84041c8b1f19f99cbf0c699
https://www.rpcardio.com/jour/article/view/341

View record at OpenAIRE Full Text Finder

8

Academic Journal

Распространенность сердечно-сосудистых факторов риска у лиц пожилого возраста с «Немыми» инфарктами мозга

Authors: МИЩЕНКО В.Н., НИКИШКОВА И.Н.

Subject Terms: "НЕМЫЕ" ИНФАРКТЫ МОЗГА,"SILENT" BRAIN INFARCTIONS,СЕРДЕЧНО-СОСУДИСТЫЕ ФАКТОРЫ РИСКА,CARDIOVASCULAR RISK FACTORS,ВОЗРАСТ,AGE,РАСПРОСТРАНЕННОСТЬ,PREVALENCE,"НіМі" іНФАРКТИ МОЗКУ,СЕРЦЕВО-СУДИННі ЧИННИКИ РИЗИКУ,ВіК,ПОШИРЕНіСТЬ

File Description: text/html

Availability: http://cyberleninka.ru/article/n/rasprostranennost-serdechno-sosudistyh-faktorov-riska-u-lits-pozhilogo-vozrasta-s-nemymi-infarktami-mozga
http://cyberleninka.ru/article_covers/16526022.png

View record from BASE

9

Academic Journal

АТЕРОСКЛЕРОТИЧЕСКАЯ БЛЯШКА В РЕГИОНАРНЫХ СОСУДИСТЫХ БАССЕЙНАХ ОБЩЕЙ СОННОЙ И БЕДРЕННОЙ АРТЕРИЙ КАК МАРКЕР СУБКЛИНИЧЕСКОГО АТЕРОСКЛЕРОЗА

Authors: Бовтюшко, П., Гришаев, С., Филиппов, А.

Subject Terms: АТЕРОСКЛЕРОТИЧЕСКАЯ БЛЯШКА,ОБЩАЯ СОННАЯ АРТЕРИЯ,БЕДРЕННАЯ АРТЕРИЯ,СЕРДЕЧНО-СОСУДИСТЫЕ ФАКТОРЫ РИСКА,ТОЛЩИНА ИНТИМА-МЕДИА АРТЕРИИ,АТЕРОСКЛЕРОЗ,ATHEROSCLEROTIC PLAQUE,COMMON CAROTID ARTERY,FEMORAL ARTERY,CARDIOVASCULAR RISK FACTORS,ARTERIAL INTIMA-MEDIA THICKNESS,ATHEROSCLEROSIS

File Description: text/html

Availability: http://cyberleninka.ru/article/n/ateroskleroticheskaya-blyashka-v-regionarnyh-sosudistyh-basseynah-obschey-sonnoy-i-bedrennoy-arteriy-kak-marker-subklinicheskogo
http://cyberleninka.ru/article_covers/15395037.png

View record from BASE

10

Report

СЕРДЕЧНО-СОСУДИСТЫЕ ФАКТОРЫ РИСКА В ПРОГНОЗИРОВАНИИ СЕНСОРНЫХ ДЕФИЦИТОВ

Subject Terms: cardiovascular risk factors, пожилые, прогнозирование, сердечно-сосудистые факторы риска, сенсорные дефициты, prognosis, sensory deficits, elderly, 3. Good health

11

Academic Journal

ГЕНДЕРНЫЕ РАЗЛИЧИЯ В ЭФФЕКТИВНОСТИ КОРРЕКЦИИ ФАКТОРОВ РИСКА И ПРИВЕРЖЕННОСТИ ПРИЕМУ РЕКОМЕНДОВАННОЙ ЛЕКАРСТВЕННОЙ ТЕРАПИИ СРЕДИ БОЛЬНЫХ, ПЕРЕНЕСШИХ ОСТРЫЙ КОРОНАРНЫЙ СИНДРОМ

Authors: Ефанов, А., Низамова, Д., Дороднева, Е., Медведева, И., Шалаев, С.

Subject Terms: СЕРДЕЧНО-СОСУДИСТЫЕ ФАКТОРЫ РИСКА,ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА,ПРОФИЛАКТИКА,ГЕНДЕРНЫЕ РАЗЛИЧИЯ,ПРИВЕРЖЕННОСТЬ ЛЕЧЕНИЮ

File Description: text/html

Availability: http://cyberleninka.ru/article/n/gendernye-razlichiya-v-effektivnosti-korrektsii-faktorov-riska-i-priverzhennosti-priemu-rekomendovannoy-lekarstvennoy-terapii-sredi
http://cyberleninka.ru/article_covers/13923891.png

View record from BASE

12

Academic Journal

Новые приоритеты в концепции факторов риска развития сердечно-сосудистых заболеваний у ликвидаторов последствий аварии на Чернобыльской АЭС в отдаленном периоде (по данным проспективного когортного исследования)

Authors: Оганов, Р., Шерашов, В., Шерашова, Н., Шерашова, М., Кукушкин, С., Рудакова, О., Жаворонкова, Е.

Subject Terms: СЕРДЕЧНО-СОСУДИСТЫЕ ФАКТОРЫ РИСКА, ОТДАЛЕННЫЙ ПЕРИОД, ЛИКВИДАТОРЫ, СИНДРОМ ANDS

File Description: text/html

Availability: http://cyberleninka.ru/article/n/novye-prioritety-v-kontseptsii-faktorov-riska-razvitiya-serdechno-sosudistyh-zabolevaniy-u-likvidatorov-posledstviy-avarii-na
http://cyberleninka.ru/article_covers/13100051.png

View record from BASE

13

Academic Journal

Prevalence of Cardiovascular Risk Factors in the Elderly with «Silent» Brain Infarctions

Authors: Mishchenko, V.M., Nikishkova, I.M.

Source: INTERNATIONAL NEUROLOGICAL JOURNAL; № 5.75 (2015); 69-73
МЕЖДУНАРОДНЫЙ НЕВРОЛОГИЧЕСКИЙ ЖУРНАЛ; № 5.75 (2015); 69-73
МІЖНАРОДНИЙ НЕВРОЛОГІЧНИЙ ЖУРНАЛ; № 5.75 (2015); 69-73

Subject Terms: «немые» инфаркты мозга, сердечно-сосудистые факторы риска, возраст, распространенность, «німі» інфаркти мозку, серцево-судинні чинники ризику, вік, поширеність, «silent» brain infarctions, cardiovascular risk factors, age, prevalence